Evotec
Daniel Rasmussen has a diverse work experience spanning multiple companies and industries. Starting in 2004, they worked as an Investor Reporting professional at GMAC Mortgage. In 2006, they transitioned to Finance and Accounting roles at MedQuist until 2008. From 2008 to 2013, they worked in Financial Planning and Analysis at Johnson & Johnson. Daniel then joined Guerbet, where they served as the Finance Director for North America and later became the Worldwide Head of Commercial FP&A & Controlling. In 2020, they moved to Evotec as the Senior Vice President and Head of Finance for the US, and subsequently assumed the same role at Just - Evotec Biologics in 2022. Throughout their career, Daniel Rasmussen has held various finance leadership positions, showcasing their expertise in financial management and planning.
Daniel Rasmussen holds a BS degree in Business Administration and Management, General from Saint Joseph's University - Erivan K. Haub School of Business. Daniel also has an MBA with a specialization in Finance from Villanova University.
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.